KERX Insider Trading Activity and SEC Form 4 Filings
KERX insider trading summary
No open-market insider purchases or sales of Keryx Biopharmaceuticals Inc (KERX) have been reported on SEC Form 4 in the past 12 months.
Latest KERX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 11, 2018 | Christine A. Carberry | Chief Operating Officer | Sell | $34K (10,469 @ $3.22) |
| Nov 15, 2018 | John F. Neylan | Chief Medical Officer | Sell | $3K (1,156 @ $2.77) |
| Nov 15, 2018 | Scott A Holmes | Chief Financial Officer | Sell | $3K (1,155 @ $2.77) |
| Oct 29, 2018 | John F. Neylan | Chief Medical Officer | Sell | $4K (1,253 @ $3.07) |
| Oct 29, 2018 | Scott A Holmes | Chief Financial Officer | Sell | $4K (1,254 @ $3.07) |
| Oct 18, 2018 | Christine A. Carberry | Chief Operating Officer | Sell | $7K (2,040 @ $3.29) |
| Aug 15, 2018 | Scott A Holmes | Chief Financial Officer | Sell | $4K (1,185 @ $3.04) |
| Aug 15, 2018 | John F. Neylan | Chief Medical Officer | Sell | $4K (1,186 @ $3.04) |
| Jul 30, 2018 | Scott A Holmes | Chief Financial Officer | Sell | $9K (2,354 @ $3.86) |
| Jul 30, 2018 | John F. Neylan | Chief Medical Officer | Sell | $5K (1,282 @ $3.86) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.